



## Radiopharmaceuticals and Nanotechnology: From Diagnostics to Theranostic Applications

Guest Editor:

### Dr. Philippe Garrigue

Radiopharmacy, University  
Hospitals of Marseille (AP-HM),  
Center for CardioVascular and  
Nutrition Research (C2VN, UMR  
AMU INSERM 1263 - INRAE 1260),  
European Center for Medical  
Imaging Research (CERIMED,  
UMS AMU CNRS 2012), Aix-  
Marseille University, 27 Boulevard  
Jean Moulin, 13005 Marseille,  
France

Deadline for manuscript  
submissions:  
**closed (28 February 2022)**

### Message from the Guest Editor

Dear Colleagues,

In the field of nuclear medicine and radiopharmaceuticals in the 2000s, developing and radiolabeling a nanomaterial was highly innovative in itself, even if its in vivo biodistribution was disseminated to... all the main organs of the body! However, the numerous proofs of concept and developments published in the past 10 years have raised a couple of questions that now need to be answered: how many nanoradiopharmaceuticals have been developed and published, with encouraging preclinical results but absolutely no clinical output? We hear that nanoradiopharmaceuticals are the future of nuclear medicine, but why does it take so long for a nanoradiopharmaceutical to find its place in clinical trials? Is toxicity an insurmountable hindrance?

We hope this Special Issue will inspire transdisciplinary teams to join their best forces, i.e., specialized engineers, (radio)pharmacists, (radio)chemists, (radio)physicists, pharmacokinetics specialists and nuclear MDs, because that is precisely what this topic needs. Let us zoom in together to the nanoscale and take a picture of what tomorrow's radiopharmaceuticals might look like.

Dr. Philippe Garrigue  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

Pharmaceutics Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma